Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Yale study probes diuretic resistance in heart failure

NCT ID NCT05323487

First seen Jun 10, 2026 · Last updated Jun 23, 2026 · Updated 1 time

Summary

This study aims to understand why some people with heart failure do not respond well to diuretics (water pills). Researchers will give 75 heart failure patients different doses of bumetanide and measure how their kidneys handle sodium. The goal is to identify biological markers of diuretic resistance, which could help tailor treatments in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bumetanide (a loop diuretic)

What this could lead to

If successful, this study could help doctors understand why some heart failure patients are resistant to diuretics, potentially leading to better personalized treatment strategies.

What could go wrong

This is a small, early-phase study (75 participants) focused on measuring biological markers, not on treating disease. It may not lead to immediate clinical changes or benefit participants directly.

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.